Male prostitution, both forced and voluntary, is a reality that is often forgotten in the discourse on gender rights and issues. Tejaswini Pagadala throws light on the lives of male sex workers in the country.

Sixteen migrant workers, walking home to Madhya Pradesh, were mowed down by a passing train in Maharashtra's Aurangabad district early on Friday.

New Delhi, May 10: The police chief of Jammu and Kashmir, Dilbag Singh said that a decision not to hand over bodies of terrorists to the families and also to bury them quietly was taken to ensure social distancing norms during

The government has given the nod for establishing COVID First-line Treatment Centres (CFTC) in the State as a contingency measure. The CFTC will be th

Resident doctor shares his experience of working at Sion hospital, where unattended bodies were found next to patients

Emotions ran high as the villagers demanded that the plant be shut down immediately as it completely ruined their lives.

An extended analysis of structural ensembles obtained from small-angle X-ray scattering data reveals subclass-specific conformational preferences of IgG antibodies, which are largely determined by the hinge-region structure.

A new study suggests that the annual long-distance migration of gray whales may be a relatively recent phenomenon, and that only a few thousand years ago, these marine mammals stayed much closer to home.

The post Ancient gray whales may have been homebodies appeared first on Smithsonian Insider.

In 1935, 101 cane toads from Hawaii were set loose in Australia to help control beetles that were decimating the Australian sugar crop. But instead […]

The post Discovery: Australia’s invasive cane toads modify their bodies to conquer new territory faster appeared first on Smithsonian Insider.

(The Paypers) Financial institutions (FIs) working in digital assets have been required by US regulatory bodies to pay attention to their anti-money laundering and...

The current process for planetary protection policy development is inadequate to respond to increasingly complex solar system exploration missions, says a new report from the National Academies of Sciences, Engineering, and Medicine.

Most people infected with the novel coronavirus develop antibodies in response.

But scientists don't know whether people who have been exposed to the coronavirus will be immune for life, as is usually the case for the measles, or if the disease will return again and again, like the common cold.

"This to me is one of the big unanswered questions that we have," says Jeffrey Shaman, a professor of environmental health sciences at Columbia University, "because it really says, 'What is the full exit strategy to this and how long are we going to be contending with it?' "

He's one of many scientists on a quest for answers. And the pieces are starting to fall into place.

Antibodies, which are proteins found in the blood as part of the body's immune response to infection, are a sign that people could be developing immunity. But they are by no means a guarantee they will be protected for life – or even for a year.

Shaman has been studying four other coronaviruses that cause the common cold. "They're very common and so people seem to get them quite often," Shaman says. Ninety percent of people develop antibodies to those viruses, at least in passing, but "our evidence is those antibodies are not conferring protection."

That may simply because colds are relatively mild, so the immune system doesn't mount a full-blown response, suggests Dr. Stanley Perlman, a pediatrician who studies immunology and microbiology at the University of Iowa. "That's why people get colds over and over again," he says. "It doesn't really tickle the immune response that much."

He's studied one of the most severe coronaviruses, the one that causes SARS, and he's found that the degree of immunity depended on the severity of the disease. Sicker people remained immune for much longer, in some cases many years.

For most people exposed to the novel coronavirus, "I think in the short term you're going to get some protection," Perlman says. "It's really the time of the protection that matters."

Perlman notes that for some people the symptoms of COVID-19 are no worse than a cold, while for others they are severe. "That's why it's tricky," he says, to predict the breadth of an immune response.

And it's risky to assume that experiences with other coronaviruses are directly applicable to the new one.

"Unforutunately, we cannot really generalize what kind of immunity is needed to get protection against a virus unless we really learn more about the virus," says Akiko Iwasaki, a Howard Hughes Medical Institute investigator at the Yale University School of Medicine.

An immunobiologist, she is part of a rapidly expanding effort to figure this out. She and her colleagues are already studying the immune response in more than 100 patients in the medical school hospital. She's encouraged that most people who recover from the coronavirus have developed antibodies that neutralize the coronavirus in a petri dish.

"Whether that's happening inside the body we don't really know," she cautions.

Research like hers will answer that question, eventually.

But not all antibodies are protective. Iwasaki says some can actually contribute to the disease process and make the illness worse. These antibodies can contribute to inflammation and lead the body to overreact. That overreaction can even be deadly.

"Which types of antibodies protect the host versus those that enhance the disease? We really need to figure that out," she says.

The studies at Yale will follow patients for at least a year, to find out how slowly or quickly immunity might fade. "I wish there was a shortcut," Iwasaki says, "but we may not need to wait a year to understand what type of antibodies are protective."

That's because she and other immunologists are looking for patterns in the immune response that will identify people who have long-term immunity.

Researchers long ago figured out what biological features in the blood (called biomarkers) correlate with immunity to other diseases, says Dr. Kari Nadeau, a pediatrician and immunologist at the Stanford University School of Medicine. She expects researchers will be able to do the same for the new coronavirus.

Nadeau is working on several studies, including one that seeks to recruit 1,000 people who were previously exposed to the coronavirus. One goal is to identify people who produce especially strong, protective antibody responses. She says the antibody-producing cells from those people can potentially be turned into vaccines.

Another critical question she's zeroing in on is whether people who become immune are still capable of spreading the virus.

"Because you might be immune, you might have protected yourself against the virus," she says, "but it still might be in your body and you're giving it to others."

That would have huge public health implications if it turns out people can still spread the disease after they've recovered. Studies from China and South Korea seemed to suggest this was possible, though further studies have cast doubt on that as a significant feature of the disease.

Nadeau is also trying to figure out what can be said about the antibody blood-tests that are now starting to flood the market. There are two issues with these tests. First, a positive test may be a false-positive result, so it may be necessary to run a confirmatory test to get a credible answer. Second, it's not clear that a true positive test result really indicates a person is immune, and if so for how long.

Companies would like to be able to use these tests to identify people who can return to work without fear of spreading the coronavirus.

"I see a lot of business people wanting to do the best for their employees, and for good reason," Nadeau says. "And we can never say you're fully protected until we get enough [information]. But right now we're working hard to get the numbers we need to be able to see what constitutes protection and what does not."

It could be a matter of life or death to get this right. Answers to these questions are likely to come with the accumulation of information from many different labs. Fortunately, scientists around the world are working simultaneously to find answers.

You can contact NPR Science Correspondent Richard Harris at rharris@npr.org.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Groundwater is the earth’s largest freshwater resource and is vital for irrigation and global food production. In dry periods farmers pump groundwater to water crops, this is already happening at an unsustainable level in many places — exceeding the rate at which rain and rivers can refill the groundwater stores. This study seeks to identify where groundwater pumping is affecting stream flows and estimates where and when environmentally critical stream flows — required to maintain healthy ecosystems — can no longer be sustained.

Climate change is expected to increase the intensity and occurrence of regional floods in Europe. A recent study has examined existing natural and constructed retention (or holding) basins that can be adapted to provide flood defences. As part of the study, a classification system for flood defence structures was developed to help Member States design sustainable flood risk management plans.

Considering the sustainability of the services provided by an ecosystem could help to overcome management challenges and hit water quality targets defined by the EU, says a new study. By exploring 13 of the ecosystem services (ES) provided by the Venice Lagoon, Italy, the researchers identify factors affecting sustainable and unsustainable patterns of ES provision, and suggest that confined and more open water bodies could benefit from different management strategies.

From nearsightedness to bone mass, a trip to the International Space System has a notable effect on astronauts' bodies.

The Earth's mountains, rivers, animals and rocks have been around for millions or billions of years. Do you know which ones have been around the longest?

Nearly half of all air pollutants exceed breathable levels and they often have a dangerous impact on our health.

Aflac’s vice president and corporate secretary makes sure the company goes above and beyond to create and maintain a culture of purpose.

A llama antibody that fights infections could help humans in the fight against the coronavirus.

The homicide team spent the day examining the scene. The police found a gun buried in the farm and a car submerged in the river; Kelvin couldn't believe his luck.

Two bodies recovered from Colorado River in Grand Canyon https://www.nps.gov/grca/learn/news/two-bodies-recovered.htm

New York's Gov. Andrew Cuomo plans to pursue the treatment following its relative success in treating influenza and Ebola.

The post FDA Okays Historic Blood Treatment for COVID; Clinical Trials to Use Antibodies From Recovered Patients appeared first on Good News Network.

The researchers from Queen Mary University of London say the discovery could lead to ground-breaking treatments with “a reduced chance of side effects.”

The post Antibodies Could Be ‘Radically Life-Changing’ New Treatment for OCD and Other Mental Disorders appeared first on Good News Network.

MADONNA said that she has tested positive for CORONAVIRUS antibodies. She went on her “QUARANTINE DIARY” series of INSTAGRAM videos and announced the positive antibody test … more

In this work, we consider a group of robots working together to manipulate a rigid object to track a desired trajectory in $SE(3)$. The robots have no explicit communication network among them, and they do no know the mass or friction properties of the object, or where they are attached to the object. However, we assume they share data from a common IMU placed arbitrarily on the object. To solve this problem, we propose a decentralized adaptive control scheme wherein each agent maintains and adapts its own estimate of the object parameters in order to track a reference trajectory. We present an analysis of the controller's behavior, and show that all closed-loop signals remain bounded, and that the system trajectory will almost always (except for initial conditions on a set of measure zero) converge to the desired trajectory. We study the proposed controller's performance using numerical simulations of a manipulation task in 3D, and with hardware experiments which demonstrate our algorithm on a planar manipulation task. These studies, taken together, demonstrate the effectiveness of the proposed controller even in the presence of numerous unmodelled effects, such as discretization errors and complex frictional interactions.

An elongated segmented soap bar is segmented longitudinally into a plurality of soap bodies separate and discrete from one another. Adjacent soap bodies are movable with respect to one another between at least two different configurations including at least an arc configuration with the plurality of soap bodies disposed in an arc. At least one coupler couples the plurality of soap bodies together to allow the adjacent soap bodies to move with respect to one another between the at least two different configurations.

A lead for providing electrical stimulation of patient tissue includes a distal lead element, at least two proximal lead elements, and a junction coupling the distal lead element to each of the at least two proximal lead elements. The distal lead element includes a plurality of electrodes and a plurality of conductive wires coupled to the plurality of electrodes and extending along a longitudinal axis of the distal lead element. Each of the at least two proximal lead elements includes a plurality of terminals and a plurality of conductive wires coupled to the plurality of terminals and extending along a longitudinal axis of the proximal lead element. The junction includes a circuit arrangement electrically coupling each of the conductive wires of the distal lead element to at least one of the conductive wires of at least one of the at least two proximal lead elements.

A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.

The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

The present disclosure describes antibodies that target HM1.24. In various aspects, the antibodies have specific CDR, variable, or full length sequences, have modifications with the parent antibody, or include at least one modification relative to a parent antibody that alters affinity to an FcγR or alters effector function as compared to the parent antibody. Nucleic acids encoding the antibodies and methods of using the antibodies are also disclosed.

The disclosure relates to anti-glial maturation factor beta (“GMF-B”) monoclonal antibodies (mAbs) and fragments thereof, as well as hybridoma lines that secrete antibodies or fragments. Therapeutic and diagnostic uses of such antibodies, including treatment and detection of cancer and dementia, and methods and kits for detecting cells or samples expressing GMF-B, including soluble GMF-B, are also encompassed.

The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

Monoclonal antibodies (mAbs) having thyroid stimulating activity (TSAb), especially full or considerably agonistic activity, or thyroid blocking activity (TBAb), which are obtainable by genetic immunization of mice, or fragments (F(ab')2, Fab or Fv) or humanized forms of such monoclonal antibodies or single chain forms (SCA; scFv) of such fragments, which antibodies, or their fragments, compete with bovine TSH for epitopes of the human TSHr, compete with autoantibodies from sera from Graves' patients as well as with autoantibodies from sera from patients harboring blocking autoantibodies for epitopes of the human TSHr, bind to conformational epitopes of the human TSHr located in the first 281 amino acids of the human TSHr, and usually also bind to TSFR receptors (TSHr) from different animals. Various uses of such antibodies, or of peptides corresponding to variable regions of such antibodies, are also described and claimed.

The present invention relates to a packing box for accommodation of plate bodies, which comprises a backplane, and a side plate vertically arranged at the periphery of the backplane, the plate body including a main body, and a PCB plate connected through a flexible sheet to the edge of the main body, a positioning member being further arranged in the space enclosed by the backplane and the side plate for preventing the PCB plate from moving relative to the main body. The positioning member of the present invention can prevent the PCB plate from moving relative to the main body of the plate body, playing a role in protecting the circuit on the flexible sheet and having low costs.

A vibrating machine for producing a molded body by compacting a granular raw mixture includes an oscillatable vibrating table configured to receive a molding box. A clamping device is produced by at least two clamping closures, each including: a pivot bracket having a lower end being pivotally mounted on the vibrating table and an upper end including a cranking which is directed outward; a double-acting hydraulic pivot cylinder pivotally mounted on the vibrating table; a two-armed rocker arm pivotally connected to the pivot bracket and including an inner part that cooperates with the molding box and an outer part that cooperates with the hydraulic pivot cylinder; and a compression spring disposed between the cranking and the outer part of the rocker arm such that the rocker arm releases from a position closing the respective clamping closure upon a pressure in the hydraulic pivot cylinder being relieved.

The present disclosure provides antibodies, and antigen-binding fragments thereof that bind to EBOV glycoprotein. The present disclosure further provides hybridoma cell lines and methods for making and using the compositions provided herein.

The invention relates to a human Interleukin-2 (hIL-2) specific monoclonal antibody (mAb), or antigen binding fragment thereof, the binding of which to hIL-2 inhibits binding of hIL-2 to CD25 and the antibody is characterized by any of the parameters: the variable chain of the mAb comprises the amino acid sequence of SEQ ID NO 005 or SEQ ID NO 006; the binding to hIL-2 is characterized by a dissociation constant (KD)≦7.5 nmol/L; the binding to hIL-2 is characterized by an off-rate (Koff)≦1×10−4 s−1 and/or the antibody displays no measurable cross-reactivity to murine IL-2.

Cysteine engineered antibodies useful for the site-specific conjugation to a variety of agents are provided. Methods for the design, preparation, screening, selection and use of such antibodies are also provided.

Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.

The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).

This invention relates to novel monoclonal antibodies that specifically bind to the alpha-folate receptor. In some embodiments, the antibodies inhibit a biological activity of folate receptor-α (FR-α). The antibodies are useful in the treatment of certain cancers, particularly cancers that have increased cell surface expression of the alpha-folate receptor (“FR-α”), such as ovarian, breast, renal, colorectal, lung, endometrial, or brain cancer. The invention also relates to cells expressing the monoclonal antibodies, antibody derivatives, such as chimeric and humanized monoclonal antibodies, antibody fragments, and methods of detecting and treating cancer using the antibodies, derivatives, and fragments.

A device for transporting vehicle bodies, on which standardized holding components are provided. A guide device is provided for at least one continuous drive train which having a driving side and a slack side, and having a first return element and at least one second return element around which the at least one continuous drive train circulates. The at least one continuous drive train supports a plurality of coupling elements which are arranged and aligned in such a manner that they can work together with the standardized holding components provided on the vehicle body.